| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
14.73(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $225.13 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
50,000 |
100,397 |
1,205,681 |
5,584,204 |
| Total Sell Value |
$7,475,024 |
$15,909,372 |
$215,448,356 |
$1,085,316,909 |
| Total People Sold |
1 |
2 |
7 |
9 |
| Total Sell Transactions |
3 |
6 |
13 |
52 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oyler John |
Chief Executive Officer |
• • • |
2017-03-06 |
4 |
S |
$40.08 |
$797,258 |
D/D |
(19,816) |
213,478 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-03-03 |
4 |
S |
$40.78 |
$1,636,968 |
D/D |
(40,091) |
233,294 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-03-02 |
4 |
S |
$41.25 |
$2,025,104 |
D/D |
(49,092) |
273,385 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-02-27 |
4 |
S |
$38.10 |
$169,328 |
D/D |
(4,444) |
161,649 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-02-24 |
4 |
S |
$38.13 |
$1,083,114 |
D/D |
(28,402) |
166,093 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2017-02-23 |
4 |
S |
$38.57 |
$212,351 |
D/D |
(5,505) |
194,495 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-02-21 |
4 |
S |
$39.83 |
$414,162 |
D/D |
(10,359) |
322,477 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-02-17 |
4 |
S |
$40.67 |
$292,981 |
D/D |
(7,204) |
332,836 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • • |
2017-02-16 |
4 |
S |
$40.23 |
$1,926,867 |
D/D |
(47,400) |
340,040 |
|
- |
|
| Malley Thomas |
Director |
– • – |
2016-11-23 |
4 |
B |
$32.00 |
$960,000 |
D/D |
30,000 |
30,000 |
2.39 |
- |
|
| Wang Xiaodong |
Director |
– • – |
2016-11-23 |
4 |
S |
$32.00 |
$3,000,000 |
D/D |
(93,750) |
0 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2016-11-18 |
4 |
B |
$32.00 |
$56,335,840 |
I/I |
1,760,495 |
3,317,977 |
2.25 |
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-27 |
4 |
AS |
$29.63 |
$784,691 |
I/I |
(26,483) |
41,463 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-26 |
4 |
AS |
$29.58 |
$611,300 |
I/I |
(20,666) |
67,946 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-23 |
4 |
AS |
$30.77 |
$351,793 |
I/I |
(11,433) |
88,612 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-22 |
4 |
AS |
$31.13 |
$778,561 |
I/I |
(25,010) |
100,045 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-21 |
4 |
AS |
$31.19 |
$508,958 |
I/I |
(16,318) |
125,055 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-20 |
4 |
AS |
$31.01 |
$255,615 |
I/I |
(8,243) |
141,373 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-19 |
4 |
AS |
$31.56 |
$1,348,487 |
I/I |
(42,691) |
149,616 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2016-09-02 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2016-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-07-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
3 |
4,881,997 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-07-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
250,000 |
4,882,000 |
|
- |
|
| Li Ji |
EVP and Gl. Head of Bus. Dev. |
• – – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
475,000 |
475,000 |
|
- |
|
| Merck Sharp & Dohme Research Gmbh |
10% Owner |
– – • |
2016-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
7,942,314 |
7,942,314 |
|
- |
|
542 Records found
|
|
Page 21 of 22 |
|
|
3.80 (2.28%) 
